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Midlife cardiovascular risk factors, including diabetes, hypertension, dyslipemia, and an unhealthy lifestyle, have been linked
to subsequent incidence, delay of onset, and progression rate of Alzheimer disease and vascular dementia. Conversely, optimal
treatment of cardiovascular risk factors prevents and slows down age-related cognitive disorders. The impact of antihypertensive
therapy on cognitive outcome in patients with hypertension was assessed in large trials which demonstrated a reduction in
progression of MRI white matter hyperintensities, in cognitive decline and in incidence of dementia. Large-scale database
correlated statin use and reduction in the incidence of dementia, mainly in patients with documented atherosclerosis, but clinical
trials failed to reach similar conclusions. Whether a multitargeted intervention would substantially improve protection, quality
of life, and reduce medical cost expenditures in patients with lower risk proﬁle has not been ascertained. This would require
appropriately designed trials targeting large populations and focusing on cognitive decline as a primary outcome endpoint.
1.Introduction
As a result of the increased life expectancy, the proportion
of older people with cognitive impairment increases con-
tinuously. Alzheimer disease, which aﬀects about 35 million
people worldwide today, is estimated to aﬄict more than
100 million people by 2050 [1–3]. Amnestic mild cognitive
impairment is found in about 20% of people older than 85
years with a conversion rate to Alzheimer disease of 10%–
15% per year [4]. As a consequence, management of patients
with cognitive disorders is quite common in daily cardiology
practice. More recently, several studies have highlighted
the deleterious role of cardiovascular risk factors on the
incidence and progression of cognitive disorders in elderly
people. This endorses the potential protection provided by
therapeutic cardiovascular risk control.
2.VascularDementiaand Alzheimer Disease
Besides Alzheimer disease, which account for about 60%–
80% of cases of dementia in the elderly, vascular dementia
has been increasingly recognized over the past decades
as a late consequence of previous symptomatic [5]o r
clinically silent [6] stroke in patients with cerebrovascular
disease, multifocal atherosclerosis, and cardiovascular risk
factors. The spectrum of vascular dementiahas subsequently
expanded to include patients without stroke past history
in whom brain magnetic resonance imaging (MRI) showed
subcortical lesions such as white matter hyperintensities
(Figure 1), lacunar infarctions and/or microhemorrhages
[7]. Similar MRI lesions were also found in patients with
cardiovascular risk factors only, especially hypertension
[8, 9], and, paradoxically, in patients with Alzheimer disease.
In addition, several studies showed that a past history of
stroke or cerebral microinfarcts were associated with an
increased risk of subsequent Alzheimer disease, its early
onset and/orits accelerated clinical progression rate [10–14].
Consistent with these ﬁndings, pathological examinations
revealed cerebral damages belonging to both forms of
dementia in some instances, for example, coexisting senile
plaques and neuroﬁbrillary tangles with vascular lesions













Figure 1: Periventricular and subcortical white matter hyperinten-
sities. MRI, T2-weighted sequence, ﬂair.
both diseases were also reported [16]. Finally, epidemio-
logical studies demonstrated a correlation between late life
occurrence of Alzheimer disease and the presence of midlife
hypertension or cardiovascular risk factors [17, 18].
Accordingly, the diagnosis of vascular dementia, as
deﬁned using speciﬁcally selected clinical criteria only [23]
has turned to a revisited framework in which vascular
dementia and Alzheimer disease interplay with each other.
Their incidence, the delay after which they appear, and their
progression rate are promoted by cardiovascular risk factors




Cognitive disorders are observed with an increased preva-
lence among diabetics who suﬀered previous stroke [25]. In
the Honolulu-AsiaAging Study (HAAS),acardiovascular risk
factor study initiated in 1965, cognitive function and brain
MRI were assessed between 2004 and 2006 in 3734 survivors
with regards to the presence of type 2 diabetes (38% of
the population). Subjects with diabetes type 2 or impaired
glucose tolerance have an increased risk of cerebral lacunes
(odds ratio, OR: 1.6), hippocampal atrophy (OR: 1.7), and
microinfarcts (OR: 1.9). The prevalence of either vascular
dementia or Alzheimer disease with cardiovascular disease
was 5.4% in diabetics and 2.9% and 2.5% in nondiabetics,
respectively [26].
Although cognitive disorders are common in older
diabetics, they develop slowly. They are limited to mild
cognitive disorders in most patients for many years before
more severe manifestations occur [35].
Several mechanisms have been advocate.
(i) Hyperinsulinemia: after crossing the blood brain
barrier, insulin competes in the brain with amyloid
β for insulin degradising enzyme, a pathway which is
enhanced in patients with the apolipoprotein APOE-
ε4 allele [36]. Conversely, rosiglitazone reduces pro-
gression of cognitive impairment and Alzheimer
disease in diabetics by decreasing insulin blood levels
and insulin resistance [37].
(ii) Advanced glycosylation end products (AGEs) result-
ing from glucose intolerance accumulate in senile
plaque and neuroﬁbrillary tangles. This pathway is
enhanced by amyloid β binding to membrane AGEs
receptors and further neuronal injury [36].
4.Hypertension
Large-scale epidemiological cohort studies initiated 4
decades ago correlated midlife hypertension to late life
cognitive impairment. Among 392 aged survivors of the
NHLBI Twin study, prevalence of dementia and white matter
hyperintensities was higher in subjects whose blood pressure
was increased at the follow-up visit in 1970, 1980, and 1985
[38]. Similar correlations between midlife hypertension and
late life prevalence ofdementia and/orextentof white matter
hyperintensities were found in several other longitudinal
follow-up studies [39–41].
Among 226participants ofPROGRESS (PerindoprilPro-
tection against Recurrent Stroke Study) in whom brain MRI
was performed, the extent of white matter hyperintensities
predicted development of dementia during followup: the
relative risk increased from 1.6 (0.4–6) in patients with mild
to moderate lesions to 7.7 (2.1–28.6) in patients with severe
lesions [41]. Progression of white matter hyperintensities
over time is increased in patients with either systolic or dias-
tolic elevated blood pressure [40–42]. A similar relationship
betweenmidlife systolicordiastolicbloodpressurelevelsand
subsequent hippocampal volume reduction was observed in
the Honolulu-Asia Aging Study [43].
The impact of antihypertensive therapy on cognitive
impairment in patients with high blood pressure (HBP) was
assessed in several trials. SCOPE (Study on Cognition and
Prognosis in the Elderly) included 4964 patients with mild
hypertension (160 < SBP < 179mmHg; 90 < DBP <
99mmHg), aged 70 to 89 years and Mini Mental State
Examination (MMSE) score ≥24. Double-blind treatment
consisted of candesartan or placebo. Open label therapy was
added to control blood pressure. Blood pressure reduction
was signiﬁcantly higher in patients receiving candesar-
tan (21.7/10.8mmHg) than in controls (18.5/9.2mmHg),
resulting in a decreased stroke incidence after a 3.7 years
followup (−23.6%). There were no signiﬁcant diﬀerences in
MMSE scores between intervention and control group [44].
However, when patients were stratiﬁed according to baseline
MMSE score, the incidence of dementia was higher among
those with a lowcognitivefunction(24 < MMSE < 28)when
compared with those with a preserved cognitive function
(MMSE > 28). Among patients with a low baseline cognitive
function, the MMSE score declined less in the candesartan
group(meandiﬀerence0.49,P = .04).Ofnote,patientswith
a low baseline cognitive function were older and had more
cardiovascular risk factors [45].
Although designed to include cognitive function in
the assessment of beneﬁts of antihypertensive therapy in
elderly, HYVET ( H y p e r t e n s i o ni nt h eV e r ye l d e r l yT r i a l )
failed to reach deﬁnite conclusions about this speciﬁc issue.
Indeed, the trial was stopped early after 2.2 years becauseCardiology Research and Practice 3
treatment resulted in a reduction in stroke and total mor-
tality. This double-blind, placebo-controlled trial enrolled
3336 patients aged 80 years or more with hypertension
(160 < SBP < 200mmHg; DBP < 110mmHg). Patients
received inda-pamide (1.5mg daily)±perindopril (2–4mg
daily) or placebo. Although blood pressure was lower in
the intervention group, the diﬀerence in dementia incidence
rate was not statistically diﬀerent between patients receiving
therapy and controls (33 versus 38 per 1000 patients-years).
However, when the authors combined their data in a meta-
analysis with otherplacebo-controlled trials ofantihyperten-
sive treatment, results reached statistical signiﬁcance [46].
Two other trials, PROGRESS and SYST-EUR, provided
convincing data on the protection of cognitive decline in
older patients treated with antihypertensive agents.
PROGRESS (Perindopril Protection against recurrent
Stroke Study) included 6105 patients (mean age: 64 years)
with previous stroke or transient cerebral ischemic attack
and assessed incidence of (vascular) dementia and cognitive
decline (MMSE score reduction >2) with regards to therapy
consistingofeitherperindopril/indapamideorplacebo.After
a 3.9-year mean followup, treatment reduced the incidence
of dementia by 12%, of cognitive decline by 19% and of
a combination of cognitive decline or recurrent stroke by
34% [47]. A substudy compared baseline and followup brain
MRIs in 192 patients to assess progression of white matter
hyperintensitiesinpatientsreceivingtherapyandincontrols.
Whereas the extent of baseline white matter hyperintensities
was similar in both groups, new hyperintensities appeared
in 16% of controls and 9% of patients receiving therapy.
Although these changes were not statistically signiﬁcant, the
mean total volume of new white matter hyperintensities was
reduced in the treatment group (0.4 versus 2mm3, P = .012)
[48].
Whereas PROGRESS by selecting patients with cere-
brovascular disease targeted the impact of antihypertensive
therapy on vascular dementia mainly, SYST-EUR (Systolic
Hypertension in Europe) was intended to include a broad
population, consisting of patients > 60 years with systolic
hypertension (160 < SBP < 219mmHg; DBP < 95mmHg).
The initial double-blind trial randomized 579 patients with
either nitrendipine (10–40mg daily), completed by enalapril
(5–20mg daily) and hydrochlorothiazide (12.5–25mg daily)
if required to control BP or placebo [49]. After a 2-
year followup, the trial was continued on the basis of an
open-label active treatment study in which a total of 2902
patients received therapy. After a mean follow up of 3.9
years, blood pressure control, though improved, remained
suboptimal in the control group (156±12/82.5±6v e r s u s
149±9.7/79±6mmHg at the last follow up visit), in
connection with fewer patients receiving antihypertensive
drugs (nitrendipine: 48.1% versus 70.2%; enalapril: 26.4%
versus 35.4%; hydrochlorothiazide: 11.4% versus 18.4%).
This was associated with a decreased incidence of dementia
in the intervention group when compared with the control
group (dementia all causes: 3.3 versus 7.4 per 1000 patient-
year; Alzheimer disease: 1.9 versus 5 per 1000 patient-year;
mixed or vascular dementia: 1.1 versus 2.1 per 1000 patient-
year) [50].
5.Hyperlipemia
Although increased levels of total and LDL-cholesterol
are associated with cardiovascular risk, atherosclerosis,
and vascular dementia, similar correlations failed to be
demonstrated with the incidence of Alzheimer disease [51].
However,Helzneretal.showed thatbothparametersare cor-
related with Alzheimer disease progression, each 10mG/dL
decrease in either being associated with a 0.10-SD decrease
in cognitive score per year of followup [52].
Large-scale database correlated statin use and reduction
in the incidence of dementia. Using the US Veteran Aﬀairs
database which collected information on approximately 4.5
million subjects and 110 million prescription annually,
Wolozin et al. showed a strong reduction in the incidence of
dementia in patients receiving simvastatin (HR = 0.46), a
moderate reduction in those receiving atorvastatin (HR =
0.91), whereas no change was observed among patients
treated with lovastatin [53]. Similar results were obtained
using a nested case-control study on 309 patients with
Alzheimer disease at the US Veteran Aﬀairs Medical Center
ofBirminghambetween1997and 2002.Patientstreatedwith
statins had a 39% lower risk of Alzheimer disease related
to nonstatin users. Of note, this association was observed
in patients with ischemic heart disease, cerebrovascular
disease, or hypertension but not among those without
any of these conditions [54]. Conversely, data from the
specialized register of the Cochrane dementia and cognitive
improvement group, which analyzed the 2 double-blind,
randomized, placebo-controlled trials HPS and PROSPER,
failed to reach similar conclusions. Indeed, among the 5804
patients aged 70 to 82 years included in PROSPER,t h e r e
was no diﬀerence in cognitive performance nor in incidence
of dementia between pravastatin treated and placebo group.
Also, no diﬀerence in incidence of dementia or in cognitive
performance tests decline was noted in HPS, in which 5806
patients over 70 years received simvastatin or placebo [55].
Thus, although several epidemiological and clinical trials
provided evidence and a rationale basis for a preventive role
of statins in Alzheimer disease [56], one should also argue
that many others showed that this beneﬁt was limited to
patients with cerebrovascular, coronary artery disease, or
hypertension.
6.Diet and Physical Activity
A lower level of physical performance in ageing adults
is associated with an increased risk of dementia. In a
prospective cohort study of 2288 people 65 years and older
with a 6-years followup, Wang et al. observed an age-speciﬁc
incidence rate of dementia, reaching 53.1 per 1000 person-
year for participants who scored lower on a performance-
based physical function test at baseline compared with 17.4
per 1000 person-years for those who scored higher. These
impairments in physical function, which are interconnected
with onset of cognitive decline, occur during the early,
subclinical, stage of the disease. Conversely, a higher level
of physical function is associated with a delayed onset of
Alzheimer disease [57].4 Cardiology Research and Practice
Table 1: Age-dependent prevalence of dementia (%) in selected populations.
Population Criteria Disease 65–69 yrs 70–74 yrs 75–79 yrs 80–85 yrs >85 yrs
Hofmanet al. [19] 12 European surveys clinical 1.4 4.1 5.7 13 21.6
Ritchie and Kildea [20] 9 US and European surveys clinical 1.5 3.5 6.8 13.6 22.3
Anstey et al. [21] Australia MMSE 3.78 5.16 10.6 16.3 22.3
Dong et al. [22] China clinical AD (w/m) 0.5/0.3 1.8/0.9 4.4/2.3 11/3.8 23.4/10.6
Dong et al. [22] China clinical VD (w/m) 2/0.9 2/0.4 1.9/0.6 1.1/1.8 0.4/0
AD: Alzheimer disease. VD: vascular dementiaw/m: women/men.
Table 2: Prevalence of dementia (clinical criteria) in people aged >
65 years.
Country Prevalence rate (%)
Fitzpatrick et al. [27]U S A 6 . 3
Graham et al. [28],
H´ ebert et al. [29] Canada 5.3
Berr et al. [30],





Lobo et al. [32]S p a i n 5 . 2
Nitriniet al. [33] 6c o u n t r i e s ,
South America 7.1
Kalaria et al. [34]I n d i a 3 . 4
Dong et al. [22],
Kalaria et al. [34] China 3.1
Several studies have shown that a healthy lifestyle,
including diet and exercise training, may prevent cognitive
decline in the elderly. Their results migh however have
been biased by confounding factors such as educational and
socioeconomic status and the impact of diet and exercise
on cardiovascular risk factors. These drawbacks were not
supported by recent studies suggesting that diet and exercise
prevent and slow down dementia independently of such
confounding factors.
The WHICAP (Washington Heights-Inwood Columbia
Aging Project) cohort study enrolled 1880 Medicare beneﬁ-
ciaries in Northern Manhattan in 1991. Food consumption,
a Mediterranean-type diet adherence score and a physical
activity score were documented. Neuropsychological tests
were repeatedevery18months frominclusionthrough2006.
Dementia developed in 282 subjects. Patients adhering to
the Mediterranean-type diet and participating to physical
activities with the highest scores have a lower risk of
subsequent Alzheimer disease in a model adjusted for age,
sex, ethnicity, education, apolipoprotein E genotype, caloric
intake, body mass index, smoking status, leisure activities,
and a comorbid index [58].
Similar results were obtained among 1410 participants
included in the Bordeaux cohort study. After a 5-year
followup, higher adherence to the Mediterranean-type diet
was associated with a slower MMSE cognitive decline [59].
7.RiskProﬁlesforDementia
7.1. Multifactorial Prevention. Although numerous studies
have linked cardiovascular risk factors proﬁle to subse-
quent incidence of dementia, most interventions to prevent
cognitive decline were performed on a single risk factor
controlbasis. Whether multifactorial preventionwill provide
substantially improved protection has not been ascertained,
especially in patients with a lower risk proﬁle.
Targeting high-risk patients for cardiovascular preven-
tion of vascular dementia and Alzheimer disease requires
assessment of aggregation of cardiovascular risk factors and
detection of subclinical atherosclerosis in individuals.
In a cohort-study of 1270 dementia-free subjects aged 75
years or more, Qiu et al. scored cardiovascular risk factors
at baseline and tracked incident dementia during a 9-year
followup.Atwofoldincreasedriskfordementia(428subjects
including 328 with Alzheimer disease) was observed in sub-
jectswithanatheroscleroticproﬁle(systolicBP > 160mmHg
or diabetes or previous stroke) and cerebral hypoperfusion
(diastolic BP < 70mmHg or pulse pressure <70mmHg,
or heart failure) [60]. Similarly, de la Torre suggested that
detection of subclinical atherosclerosis and carotid plaques
using carotid artery ultrasound may identify patients at
increased risk for subsequent cognitive impairment, thereby
allowing reinforced preventive control of cardiovascular risk
factors, a strategy which may ultimately reduce the incidence
of dementia [61]. Whether translating such an approach to
lower risk patients would be clinically relevant remains to
be ascertained using appropriately designed trials targeting
large populations and focusing on cognitive decline as
primary outcome endpoints [62].
7.2. Age-Related Risk. Although prevalence and incidence
of Alzheimer disease increase with age, further increase
after the age 90 has been questioned, as approximately half
of the centenarians (43%) did not experience dementia
[63]. In addition, pathological studies also showed that the
distribution pattern of neuroﬁbrillary tangles, senile plaque,
microvascular impairment, and neuronal loss changes in
extreme aging relative to the younger old [64]. As a result,
the beneﬁts expected from cardiovascular prevention of
cognitive disorders in the oldest-old and centenarians may
be more limited than in younger old.
7.3. Risk Control Across Populations. The beneﬁt of cardio-
vascularrisk factorscontrolinpreventingcognitivedisordersCardiology Research and Practice 5
amongelderlymay also largelyvary across populationsliving
in diﬀerent geographical areas.
Dementia prevalence rates among people over 65 years
ranges from 3% to 11%, depending on diagnosis cri-
teria (clinical, mostly DSM III, or MMSE-guided), age
(Table 1), and countries (Tables 1 and 2). However, age-
related increases in prevalence are observed independently
of the population studied (Table 1), with limited diﬀerences
in prevalence across populations and geographical areas
(Table 2).
The burden of cardiovascular risk factors and its impact
on vascular dementia have also been reported to increase
with age in patients in western countries [29, 65–67]. Con-
comitantly,population-based surveyscomplementedby data
from MONICA and INTERSALT showed a linear association
of systolic blood pressure with age in men and women




Althoughthismay argueforsome rationale forexpecting
similar results from cardiovascular prevention of cognitive
declineamongdiﬀerentpopulations,includingindeveloping
countries, trials to support such hypotheses remain to be
performed.
8.Conclusion
Optimal treatment of cardiovascular risk factors pre-
vents and decreases progression of vascular dementia and
Alzheimerdisease.Asa5-yeardelayintheonsetofAlzheimer
disease could reduce the prevalence of Alzheimer disease
by 50%, epidemiological forecasting estimate about 25% of
the 5-fold increases in prevalence of dementia expected to
occur until 2050 could eﬀectively be prevented by optimal
cardiovascular risk factors control [3, 61].
Thus, facing the worldwide burden ofcardiovascular risk
factors in a population growing in weight and in age contin-
uously, slowing the incidence and progression of dementia
may be a valuable challenge for cardiovascular prevention
and cardiology practice. As life expectancy is expected to
increase further in the decades to follow, limiting its age-
related counterparts such as Alzheimer disease may also be
relevant in an individual perspective as well as in a commu-
nity opportunity to reduce medical cost-expenditures.
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